Navigation Links
TRPM8 in Medical News

Role of Protein in the Development of Prostate Cancer Identified

...t studies have indicated that the protein known as trpm8 plays an important role in prostate cancer: high levels of trpm8 have been found in prostate carcinoma compared to normal prostate epithelial cells, and trpm8 has been suggested as a specific marker and therap...

Detecting Cold, Feeling Pain: Study Reveals Why Menthol Fresh

...tes how the body experiences intense stimuli temperature, in this case that can cause pain. As such, the receptor known as menthol receptor trpm8 -- provides a target for studying acute and chronic pain, as can result from inflammatory or nerve injury, the researchers say, and a potential new ta...

Menthol Receptor-A Thermosensitivity Determinant in Cold Temperature

...olves the mystery of how important the ion channel trpm8 is for alerting the body to cold temperatures.TRPM...d that isolated, cultured nerve cells that express trpm8 react to cooling stimuli, but cells cultured from mice lacking trpm8 do not. Also, mice engineered without...

Chronic pain can be cooled off !

...nt in the skin, which effectively transmits the cooling sensation. The scientists remarked: 'We have found that if you can selectively activate the trpm8 receptor, then you have a chance of suppressing other sensory inputs coming into the nervous system that are carrying pain information. We found a ver...
TRPM8 in Medical Technology

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

-- Data Presented at American Urological Association Annual Meeting -- SEATTLE and CHICAGO, April 28 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN ) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small m...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN ) today announced that the Company has enrolled the first patient in a Phase 1 clinical trial of D3263 in patients with advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

...immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial

...mmunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington...
TRPM8 in Biological News

Detecting cold, feeling pain: Study reveals why menthol feels fresh

...es how the body experiences intense stimuli – temperature, in this case – that can cause pain. As such, the receptor – known as menthol receptor trpm8 -- provides a target for studying acute and chronic pain, as can result from inflammatory or nerve injury, the researchers say, and a potential new ta...

Scripps research team sheds light on long-sought cold sensation gene

...ve withstood the test of genetics," he says. trpm8 was first discovered by Patapoutian’s group and pr...ould choose between two temperatures, mice without trpm8 showed essentially no preference in the temperatur...normal mice to flick their paw and lick them. trpm8 codes for an ion channel found at the tips of sens...

Novel method reveals how menthol discovery could point towards new or improved pain therapies

...utagenesis and high-throughput screening approach, the study assayed 14,000 trpm8 mutants to find mutants that were not enhanced by menthol but were otherwis...ur experiments yielded significant insights into the functional elements of trpm8 ion channel protein that would have been difficult to obtain using other mu...
TRPM8 in Biological Technology

Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET

...mmunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...

Dendreon Announces Webcast Presentations at Upcoming Investor Conferences

...mmunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...

Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest

...immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...

Dendreon Announces Closing of Common Stock Offering

...mmunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington...

Dendreon Announces Common Stock Offering

...immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...

Dendreon Announces Webcast Presentations at Upcoming Investor Conferences

...mmunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...

Dendreon Reports First Quarter 2009 Financial Results

... announcing that D3263, a small molecule targeting trpm8 (a transmembrane cation channel protein), reduced ...acokinetics of orally-administered D3263 targeting trpm8 in patients with solid tumors that are refractory ...ng an orally-available small molecule that targets trpm8 that could be applicable to multiple types of canc...

Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting

...:30 a.m. to 12:30 p.m. CDT - Abstract #1408: "Preclinical Evaluation of the trpm8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia." Poster prese...Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign pros...

Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer

...immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...

PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

...immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets trpm8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington ...
TRPM8 in Biological Products

Rabbit Anti-TRPM8 Polyclonal Antibody, Unconjugated from Abcam

Description:... Rabbit polyclonal to trpm8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Company:Abcam
Other Tags
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... who was diagnosed with Ebola while working for NBC News ... can leave the special isolation unit at Nebraska Medical Center in ... the hospital said Tuesday. A blood test confirmed by the ... 33, can head home to Providence, R.I., NBC News ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
(Date:10/22/2014)... identity analyst firm Acuity Market Intelligence forecasts that in ... have a chip-based National eID card, including near-complete regional ... Asia , with its vast population, is expected ... of all National eID cards issued between 2014 and ... National eID Industry Report: 2014 Edition" — projects ...
(Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
Other Contents